Rodent-only research. Everything below comes from experiments in rats and mice. None of it shows that golden oyster mushrooms lower liver fat, cholesterol, or disease risk in people.
Ergothioneine has become one of the most talked-about compounds in the longevity world, and mushrooms are its best-known dietary source. So a new rodent study has a plot twist for supplement shoppers. The mushroom lowered liver fat in the animals. The purified ergothioneine, given on its own, did not.
The paper, published in Food, Nutrition and Health (DOI: 10.1007/s44403-026-00089-6), tested Tamogitake, also sold as golden oyster mushroom (Pleurotus cornucopiae var. citrinopileatus). It compared the whole mushroom with isolated ergothioneine, and the results suggest the mushroom does something the single compound can't account for.
The Setup: A Mushroom Famous for One Molecule
Tamogitake is an edible mushroom rich in ergothioneine, a sulfur-containing amino acid. Ergothioneine has been linked in earlier research to anti-inflammatory effects and improved cognitive function, largely through its antioxidant activity. The authors point out that the benefits of eating Tamogitake itself were still unclear. They wanted to know what the mushroom does to lipid metabolism, meaning how the body handles cholesterol and triglycerides (triacylglycerol).
Experiment 1: Rats and a 5% Mushroom Diet
The team fed four-week-old male Sprague-Dawley rats an AIN-76-based diet containing 5% dried Tamogitake powder. Some diets also contained 0.5% added cholesterol, and the feeding lasted four weeks.
The rats eating Tamogitake showed:
- Significantly lower liver weight
- Significantly lower hepatic cholesterol
- Significantly lower hepatic triacylglycerol
These effects appeared with or without the added dietary cholesterol. The researchers also checked hepatic mRNA expression of HMG-CoA reductase, the rate-limiting enzyme in cholesterol synthesis (and the statin target), and CYP7A1, a key enzyme in converting cholesterol to bile acids. Neither changed. The mushroom's effect therefore doesn't seem to come from the most obvious gene-level switches in liver cholesterol metabolism, and the mechanism remains open.
Experiment 2: The Plot Twist in Obese Mice
The second experiment was harder on the mushroom. The researchers used three-week-old male KK-Ay mice, a model of obesity and hyperglycemia whose livers accumulate excess lipids. For 52 days, the mice ate diets with 0.5% cholesterol plus one of two additions:
- 5% Tamogitake powder, or
- 0.05% pure ergothioneine.
The mushroom's liver-lowering effect on cholesterol and triacylglycerol reproduced in these mice, even though their livers were prone to fat buildup. The ergothioneine diet did not produce that effect.
The abstract doesn't say how the ergothioneine dose compared with the amount in the mushroom powder, so it would be wrong to read this as proof that ergothioneine does nothing in the liver. The authors' own conclusion is more measured: the benefits of Tamogitake "cannot be attributed to ergothioneine alone."
A Clue From the Fecal Data
The researchers also measured what the animals excreted. Fecal excretion of apparent total cholesterol and free fatty acids tended to be higher with Tamogitake feeding, but not with ergothioneine feeding. Bile acid excretion was not increased.
The word "tended" matters here, because it signals a trend rather than a firm effect. Still, it hints that something in the whole mushroom may reduce how much fat and cholesterol the body keeps, perhaps by affecting absorption or handling in the gut. This is speculation, since the paper doesn't establish the mechanism. Mushrooms contain fibers and many other compounds besides ergothioneine, and the study doesn't pin down which one is responsible.
Blood glucose and serum insulin did not differ significantly among groups. The mushroom's effect was on liver lipids, not on glycemic measures, at least in this experiment.
Why This Matters for the Supplement Conversation
The broader lesson is familiar in nutrition science. A food is not just its most famous molecule. When a headline compound gets isolated and sold in capsules, there's an implicit assumption that the capsule delivers the food's benefits. This study is a small, animal-based counterexample. In these rodents, the whole mushroom did something the purified compound did not.
The finding doesn't make ergothioneine supplements useless, and it doesn't test the cognitive or anti-inflammatory effects reported elsewhere. It says that, for liver fat in these models, ergothioneine wasn't the active ingredient, or at least not the only one.
Practical Takeaways
Whole food vs. isolated ergothioneine
If the goal is to get what the mushroom offers, this study favors the mushroom over the isolate. Whole foods contain many compounds that may work together, and this experiment supports that idea, but only in animals.
How to eat golden oyster mushrooms
The paper used dried powder, not cooked dishes, so it offers no guidance on preparation. As general culinary practice, golden oyster mushrooms are typically cooked, for example sautéed, roasted, or added to soups and stir-fries, and cooking mushrooms thoroughly is standard food-safety advice. Don't expect a stir-fry to replicate the experiment.
Why 5% of the diet is a lot
In the rodent diets, the mushroom powder made up 5% of the feed. That is a constant, substantial share of everything the animals ate, every day, for four weeks in rats and 52 days in mice. It is not a garnish or a weekly side dish. Rodent diets are also formulated differently from human diets, so there is no simple conversion to a human portion, and this article doesn't offer one. The study doesn't establish a human dose.
Who might care
People worried about fatty liver or high cholesterol will find this topic interesting, but it is not a treatment. Fatty liver disease and lipid disorders need proper evaluation. If you have risk factors, such as obesity, high blood sugar, or abnormal liver tests, see a doctor rather than relying on a mushroom powder or a supplement.
The Bottom Line
This study shows that, in rats and obese mice, golden oyster mushroom powder lowered liver cholesterol and triglycerides, and pure ergothioneine at 0.05% did not. The fecal data hint at a gut-level mechanism, and the lack of change in HMG-CoA reductase and CYP7A1 expression suggests the mushroom isn't acting through those obvious routes. Whether any of this applies to people, at realistic portions, is an open question that only human trials can answer.